FDA
FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to patients.
FEATURED STORIES
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack of consistency. With new safety guidelines for gene editing therapies, the FDA has taken a first step toward fixing both problems.
BioSpace looks back at 2025 and where the FDA is going in 2026.
The FDA has gained a reputation during the past year for being inconsistently flexible, particularly when it comes to rare diseases. Executives at Rezolute and CERo Therapeutics recently had positive interactions with the agency, in which they told BioSpace reviewers have been “collaborative” and “curious.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Christmas came a week early for Aerie Pharmaceuticals.
The approval of HAnano Surface in the United States has been executed in accordance with the new 510(k) legislation for medical devices.
A look at the latest batch of FDA approvals this year.
This could be the first step in a long journey that could amount to huge profitability for the iPhone maker.
Foundation Medicine’s sequencing diagnostics test for solid tumors that can detect cancer-causing mutations in 324 genes was approved by the FDA Thursday.
HIV patients have a new maintenance drug in their arsenal of medication.
A look at the 19 spine-related medical devices the FDA cleared in October.
The FDA approved a label expansion for Pfizer’s cancer drug Sutent to include the adjuvant treatment of adult patients at high risk of RCC following the surgical removal of the cancerous kidney.
Genentech scored two approvals from the FDA this week.
The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.